Sign in
Taking people in United StatesNo phase

Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

Key facts

Who runs it
Innova Vascular, Inc.
Where
Albany, Birmingham, Bradenton, Chapel Hill, Chicago, Columbus, Dallas, Irvine, Knoxville, Long Beach, Mission Viejo, Naples, Orange, Tampa, Tucson, and Washington D.C., United StatesSee the 16 sitesAlso in 1 other country, 5 sites
Trial code
Status
Recruiting
People taking part
107 people, planned
Started
19 Aug 2024
Planned end
Sept 2026
Type of study
Interventional
Treatments tested
  • Laguna Thrombectomy System
Record updated
17 July 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • ≥ 18 years of age; < 85 years old
  • RV/LV ratio > 0.9 as determined by CTA
  • Systolic blood pressure > 90 mmHg
  • Heart rate ≤ 120
  • Patient is deemed eligible for procedure by the interventional investigator
  • CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
  • PE Symptom duration ≤ 14 days

Who cannot take part

  • Current participation in another drug or medical device treatment study
  • History of prior PE within the past 90 days
  • Cardiovascular or pulmonary surgery within the last 7 days
  • Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • In active chemotherapy or radiation treatment for a malignancy during the course of the study
  • Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation
  • History of known severe or chronic pulmonary arterial hypertension
  • History of underlying lung disease that is oxygen dependent
  • History of chest irradiation
  • Platelets: < 100,000/microliter
  • Serum Creatinine: > 2 mg/dL
  • International Normalized Ratio (INR): > 3
  • History or chronic left heart disease with left ventricular ejection fraction < 30%
  • Systolic pulmonary artery pressure > 70 mmHg on initial invasive hemodynamic assessments
  • Life expectancy of < 90 days in the opinion of investigator at the time of enrollment
  • Subject pregnant or breast feeding
  • Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days
  • Presence of recently placed (<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium
  • FiO2 Requirement: > 40% (6 LPM) to keep oxygen saturation > 90%
  • Hematocrit: < 28%
  • Major Trauma Injury Severity Score (ISS): > 15
  • Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants
  • Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
  • Known presence of clot in transit within right atrium or ventricle

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United States

Also in 1 other country, 5 sites

  • Albany Medical CenterAlbany, United StatesContact: Sanjay Shrivastava, Ph.D.No longer taking part
  • Grandview Medical CenterBirmingham, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • Manatee Memorial HospitalBradenton, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • University of North Carolina at Chapel HillChapel Hill, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • Rush University Medical CenterChicago, United StatesContact: Sanjay Shrivastava, Ph.D.No longer taking part
  • OhioHealth Research InstituteColumbus, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • University of Texas, SouthwesternDallas, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • University of California, IrvineIrvine, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • Turkey Creek Medical CenterKnoxville, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • Memorial Care Long Beach Medical CenterLong Beach, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • Mission Hospital Regional Medical CenterMission Viejo, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • Physicians Regional Medical CenterNaples, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • St. Joseph Hospital of OrangeOrange, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • AdventHealth TampaTampa, United StatesContact: Sanjay Shrivastava, Ph.D.No longer taking part
  • University of ArizonaTucson, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
  • George Washington UniversityWashington D.C., United StatesContact: Sanjay Shrivastava, Ph.D.Taking people

About the trial

What the trial wants to find out

This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.

The group in the trial

  • Laguna Thrombectomy SystemTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Fit questions
Built from NCT06041594, who can take part
Record updated
17 July 2026